GlassScriptPhysician profile
Shilpa Chitnis
NPI 1578585337
$36,876.15
in general payments reported to CMS, 2019-2025
26 companies · $8,439 in 2025
The $8,439 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,882 · 2020: $1,870 · 2021: $7,260 · 2022: $6,020 · 2023: $8,744 · 2024: $1,662 · 2025: $8,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,758 · Food and Beverage: $4,408 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,920 · Honoraria: $2,875 · Travel and Lodging: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,758.00 |
| Food and Beverage | $4,407.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,920.00 |
| Honoraria | $2,875.00 |
| Travel and Lodging | $883.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,234.96 | 2019-2025 | Infinity |
| Abbvie INC. | $7,442.29 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $3,981.81 | 2019-2025 | Rytary, Crexont |
| Orphalan INC | $3,077.27 | 2023-2024 | Cuvrior |
| Acorda Therapeutics, INC | $1,805.72 | 2020-2024 | Inbrija |
| Neurocrine Biosciences, INC. | $1,800.21 | 2021-2025 | Ingrezza, Ongentys |
| Boston Scientific Corporation | $499.59 | 2019-2024 | Vercise |
| Mdd US Operations, LLC | $414.40 | 2019-2025 | Gocovri |
| Teva Pharmaceuticals USA, INC. | $378.44 | 2023-2025 | Austedo Xr, Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $262.43 | 2023-2025 | Dysport |
| Kyowa Kirin, INC. | $247.01 | 2023-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $159.45 | 2019-2025 | Nuplazid, Daybue |
| Supernus Pharmaceuticals, INC. | $111.98 | 2023 | |
| Medtronic USA, INC. | $90.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $63.56 | 2023-2024 | Rexulti, Nuedexta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $48.35 | 2025 | |
| Medtronic, INC. | $40.00 | 2022 | |
| Merz Pharmaceuticals, LLC | $37.43 | 2024 | Xeomin |
| Lilly USA, LLC | $30.06 | 2025 | Kisunla |
| Argenx US, INC. | $28.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.10 | 2024 | |
| Ge Healthcare | $23.60 | 2025 | |
| Cala Health, INC. | $21.48 | 2024 | Cala Kiq, Cala Trio |
| Biogen, INC. | $21.22 | 2024 | Skyclarys |
| Pfizer INC. | $16.45 | 2025 | |
| Insightec,INC | $13.51 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Chitnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.